Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib in Active Psoriatic Arthritis (PENGUIN 2)
NCT04115839Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Nov 2019
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of filgotinib in psoriatic arthritis (PsA) (5 arms), sponsored by Gilead Sciences. Primary endpoint: American College of Rheumatology 20% Improvement at 12 weeks. Started Nov 2019; status: terminated.
02
Drugs
filgotinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT04115839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04115839.